View all companies
Paul Chew
Head of Research @ PhillipCapital
Paul has almost 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.
He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.
Hide filters Show filters
Latest from Paul Chew
Q&M Dental Group Singapore Ltd: Hurt by upfront and uneven expenses
1H22 revenue and PATMI were 52%/37% of our FY22e forecast. Earnings from COVID-19 PCR tests swung from $3mn net profit a year ago to S$50k net loss. The target price is lowered to S$0.60 (prev. S$0.71).
Paul Chew @ PhillipCapital 22 August 2022
Asian Pay Television Trust: Stable with early signs of 5G
1H revenue and EBITDA were at 49%/48% of our FY22e estimates. 5G backhaul revenue was S$2.2mn annualised (FY21: S$1.6mn). No change to our FY22e EBITDA forecast and target price of S$0.15.
Paul Chew @ PhillipCapital 16 August 2022
ComfortDelGro Corp Ltd: Recovery is underway, except China
Results were below expectations due to taxi rebates of S$10mn in China due to the lockdown. Excluding government relief and non-recurring items, operating profit in 2Q22 jumped 2.5-fold to S$62mn. Return to office and other activities started only in...
Paul Chew @ PhillipCapital 16 August 2022
Thai Beverage: Recovery except for spirits
Beer recovered on both volume and price increases. Our target is pegged at 18x FY22e earnings, its 5-year average. No change to our FY22e forecast.
Paul Chew @ PhillipCapital 15 August 2022
HRnetGroup Ltd: Faster growth outside Singapore
1H22 revenue and PATMI was 51%/48% of our FY22e forecast. 1H22 PATMI grew 12% YoY to S$32.6mn, excluding fair value losses and one-off reversal of trade accruals. Maiden interim DPS of 3 cents was announced.
Paul Chew @ PhillipCapital 15 August 2022
Raffles Medical Group Ltd: Huge earnings beat from foreign patients and electives
+ Resilient revenue despite less COVID related revenue. Revenue expanded 11% YoY despite the decline in PCR testing services. + Surge in operating margins. Operating margins surged 6% bps to 22.6%. + Growth in China despite lockdown. 1H22 free cash f...
Paul Chew @ PhillipCapital 3 August 2022
Filter by tags
Paul Chew
Equity
Asia
Singapore
China
Industrials
Capital Goods
2021
PATMI
Consumer Discretionary
Macro-strategy
Malaysia
Macro
Materials
